trial summary · NCT07194980
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Safety and Efficacy of the Addition of Nemtabrutinib to Lisocabtagene Maraleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Trial record from the TrialBase DB dataset, status RECRUITING, condition Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, sponsored by Fred Hutchinson Cancer Center. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This phase II trial studies how well the addition of nemtabrutinib to lisocabtagene maraleucel in treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Nemtabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lisocabtagene maraleucel is a type of treatment called chimeric antigen receptor (CAR) T-cell therapy, in which a patient's T-cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T-cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T-cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T-cells are grown in the laboratory and given to the patient by infusion for treatment. Adding nemtabrutinib to lisocabtagene maraleucel may be an effective treatment for relapsed/refractory CLL/SLL.
Source record: https://clinicaltrials.gov/study/NCT07194980
Facts
| registry id | NCT07194980 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| sponsor | Fred Hutchinson Cancer Center |
| sponsor class | OTHER |
| enrollment | 20 |
| start date | 2026-12-01 |
| primary completion | 2029-10-20 |
| completion | 2029-10-20 |
| results posted | not reported |
Conditions
- Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
- Nemtabrutinib
- Lisocabtagene Maraleucel
Countries
- United States
Intervention types: BIOLOGICAL, DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.